Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Netherlands Heart Journal
Published in: Netherlands Heart Journal 11/2017

Open Access 01-11-2017 | Letter to the Editor

The first-generation ABSORB BVS: awaiting dissolving outcomes

Authors: J. Elias, I. M. van Dongen, J. P. S. Henriques

Published in: Netherlands Heart Journal | Issue 11/2017

Login to get access

Excerpt

We thank Dr Shah for his response to our meta-analysis. As Dr Shah points out, in our meta-analysis the ABSORB II trial was the only study that reported 3‑year follow-up. All the other trials had a follow-up duration of 2 years or less, and the AIDA trial reported a median follow-up of 2 years [1]. Therefore, the very-long-term clinical efficacy and safety of the bioresorbable vascular scaffold (BVS) are currently unknown. …
Literature
1.
Elias J, van Dongen IM, Kraak RP, et al. Mid-term and long-term safety and efficacy of bioresorbable vascular scaffolds versus metallic everolimus-eluting stents in coronary artery disease: a weighted meta-analysis of seven randomised controlled trials including 5577 patients. Neth Heart J. 2017;25:429–38.CrossRefPubMedPubMedCentral
2.
Gao R. Randomized comparison of everolimus-eluting bioresorbable vascular Scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: 3‑year clinical outcomes from ABSORB China. Presented at: annual EuroPCR conference; May 17, 2017; Paris, France. 2017. https://​www.​tctmd.​com/​slide/​randomized-comparison everolimus- eluting-bioresorbable-vascular-scaffolds-vs-everolimus. Accessed 10 Aug 2017.
3.
4.
Serruys PW, Chevalier B, Sotomi Y, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016;388:2479–91.CrossRefPubMed
Metadata
Title
The first-generation ABSORB BVS: awaiting dissolving outcomes
Authors
J. Elias
I. M. van Dongen
J. P. S. Henriques
Publication date
01-11-2017
Publisher
Bohn Stafleu van Loghum
Published in
Netherlands Heart Journal / Issue 11/2017
Print ISSN: 1568-5888
Electronic ISSN: 1876-6250
DOI
https://doi.org/10.1007/s12471-017-1042-8

Other articles of this Issue 11/2017

Netherlands Heart Journal 11/2017 Go to the issue

Original Article

The preoperative cardiology consultation: indications and risk modification

Commentary

Percutaneous treatment of valvular heart disease: Die another day

Rhythm Puzzle - Question

Appropriate or inappropriate ICD shock; what is the post-shock rhythm?

Original article

In search of an efficient strategy to monitor disease status of chronic heart failure outpatients: added value of blood biomarkers to clinical assessment

Heart Beat

Unusual timing of a common complication after pulmonary vein isolation

Point of View

Mitro-aortic pathology: a point of view for a fully transcatheter staged approach

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits